Your browser doesn't support javascript.
loading
Telomere-related DNA damage response pathways in cancer therapy: prospective targets.
Gu, Liting; Liu, Mingdi; Zhang, Yuning; Zhou, Honglan; Wang, Yishu; Xu, Zhi-Xiang.
Afiliação
  • Gu L; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
  • Liu M; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
  • Zhang Y; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
  • Zhou H; Department of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
  • Wang Y; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
  • Xu ZX; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Front Pharmacol ; 15: 1379166, 2024.
Article em En | MEDLINE | ID: mdl-38910895
ABSTRACT
Maintaining the structural integrity of genomic chromosomal DNA is an essential role of cellular life and requires two important biological mechanisms the DNA damage response (DDR) mechanism and telomere protection mechanism at chromosome ends. Because abnormalities in telomeres and cellular DDR regulation are strongly associated with human aging and cancer, there is a reciprocal regulation of telomeres and cellular DDR. Moreover, several drug treatments for DDR are currently available. This paper reviews the progress in research on the interaction between telomeres and cellular DNA damage repair pathways. The research on the crosstalk between telomere damage and DDR is important for improving the efficacy of tumor treatment. However, further studies are required to confirm this hypothesis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China